CureVac (CVAC) Competitors $3.82 -0.05 (-1.29%) Closing price 04:00 PM EasternExtended Trading$3.87 +0.05 (+1.31%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CVAC vs. DNLI, IMVT, TWST, XENE, ACAD, VCEL, ZLAB, MLTX, MOR, and BHCShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Denali Therapeutics (DNLI), Immunovant (IMVT), Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Zai Lab (ZLAB), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Denali Therapeutics Immunovant Twist Bioscience Xenon Pharmaceuticals ACADIA Pharmaceuticals Vericel Zai Lab MoonLake Immunotherapeutics MorphoSys Bausch Health Companies Denali Therapeutics (NASDAQ:DNLI) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Does the MarketBeat Community favor DNLI or CVAC? Denali Therapeutics received 433 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 68.15% of users gave Denali Therapeutics an outperform vote while only 54.35% of users gave CureVac an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes45868.15% Underperform Votes21431.85% CureVacOutperform Votes2554.35% Underperform Votes2145.65% Do insiders & institutionals believe in DNLI or CVAC? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is DNLI or CVAC more profitable? CureVac has a net margin of 20.72% compared to Denali Therapeutics' net margin of 0.00%. CureVac's return on equity of 21.98% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% CureVac 20.72%21.98%15.72% Which has more risk and volatility, DNLI or CVAC? Denali Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Does the media refer more to DNLI or CVAC? In the previous week, Denali Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Denali Therapeutics and 7 mentions for CureVac. CureVac's average media sentiment score of 1.09 beat Denali Therapeutics' score of 0.51 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, DNLI or CVAC? Denali Therapeutics has higher revenue and earnings than CureVac. Denali Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M10.27-$145.22M-$2.76-8.54CureVac$58.18M14.70-$281.58M$0.556.95 Do analysts recommend DNLI or CVAC? Denali Therapeutics presently has a consensus price target of $38.00, suggesting a potential upside of 61.15%. CureVac has a consensus price target of $10.00, suggesting a potential upside of 161.78%. Given CureVac's higher possible upside, analysts plainly believe CureVac is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.93CureVac 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryDenali Therapeutics beats CureVac on 10 of the 19 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$855.22M$6.93B$5.62B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E Ratio6.9510.1189.6917.66Price / Sales14.70351.361,220.3881.09Price / CashN/A65.4844.3437.71Price / Book1.535.335.134.73Net Income-$281.58M$157.56M$118.85M$225.42M7 Day Performance-3.54%2.83%1.87%-0.44%1 Month Performance22.44%2.84%7.96%3.57%1 Year Performance4.66%8.37%26.70%19.20% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac4.3012 of 5 stars$3.82-1.3%$10.00+161.8%+4.6%$855.22M$58.18M6.951,172Positive NewsDNLIDenali Therapeutics4.499 of 5 stars$23.19+4.4%$38.91+67.8%+33.6%$3.34B$330.53M-8.40430Analyst ForecastShort Interest ↑IMVTImmunovant1.751 of 5 stars$22.40-2.8%$47.00+109.8%-44.6%$3.29BN/A-10.09120TWSTTwist Bioscience2.5907 of 5 stars$52.23-3.4%$51.90-0.6%+42.4%$3.10B$312.97M-14.51990Upcoming EarningsInsider TradeNews CoverageXENEXenon Pharmaceuticals2.6644 of 5 stars$40.11+0.4%$56.00+39.6%-13.6%$3.06B$9.43M-14.22210Insider TradeAnalyst RevisionPositive NewsACADACADIA Pharmaceuticals4.0074 of 5 stars$18.27-2.1%$25.25+38.2%-33.3%$3.04B$726.44M23.42510Short Interest ↑Analyst RevisionVCELVericel2.3243 of 5 stars$59.72+4.0%$62.14+4.1%+32.4%$2.95B$197.52M995.50300Insider TradeZLABZai Lab2.5206 of 5 stars$26.84+2.2%$55.00+104.9%+19.9%$2.94B$266.72M-9.692,175MLTXMoonLake Immunotherapeutics2.1649 of 5 stars$44.89-1.8%$84.29+87.8%-20.8%$2.87BN/A-34.802MORMorphoSysN/A$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730BHCBausch Health Companies2.8252 of 5 stars$7.77+0.6%$7.75-0.2%-10.4%$2.81B$8.76B-16.1820,270Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies DNLI Competitors IMVT Competitors TWST Competitors XENE Competitors ACAD Competitors VCEL Competitors ZLAB Competitors MLTX Competitors MOR Competitors BHC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CVAC) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
